Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia | Aplastic Anemia & MDS International Foundation
Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia

Clinical Trial: NCT02773290

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

To evaluate the hematological responses based on the response assessment criteria when AMG531 is subcutaneous (SC)-administered with anti-human thymocyte immunoglobulin (ATG) + ciclosporin A (CsA) therapy for 6 months in patients with aplastic anemia (AA) who were previously untreated with immunosuppressive therapy.

Status: 
Recruiting
Study Date: 
Thu, 04/25/2019 to Mon, 03/01/2021
Bone Marrow Disease(s): 
  • aplastic anemia
Intervention: 
Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.